- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:06 | Radiopharm Theranostics Reports Business Update | 92 | GlobeNewswire (Europe) | Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI... ► Artikel lesen | |
| 13:01 | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 00:04 | RADIOPHARM THERANOSTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| Mo | Radiopharm presents early data on HER2-targeted cancer therapy | 1 | Investing.com | ||
| So | RADIOPHARM THERANOSTICS LIMITED: RAD Initial Findings from Phase 1 177Lu-RAD202 Trial | - | ASX | ||
| 16.04. | Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases | 153 | GlobeNewswire (Europe) | Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial... ► Artikel lesen | |
| 16.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 15.04. | RADIOPHARM THERANOSTICS LIMITED: RAD Completes Enrollment in Phase 2b Trial of RAD 101 | - | ASX | ||
| 08.04. | Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial | 213 | GlobeNewswire (Europe) | SYDNEY, April 08, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 08.04. | RADIOPHARM THERANOSTICS LIMITED: RAD202 Phase 1 HEAT Trial Advances to Dose Level 3 | 1 | ASX | ||
| 07.04. | Radiopharm schließt Liefervertrag mit Siemens Healthineers für Hirntumor-Diagnostikum | 73 | Investing.com Deutsch | ||
| 07.04. | Radiopharm signs supply deal with Siemens for brain cancer drug | 14 | Investing.com | ||
| 07.04. | Radiopharm Theranostics Signs Supply Deal With Siemens Healthineers For RAD101 | 33 | RTTNews | ||
| 07.04. | Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. | 617 | GlobeNewswire (Europe) | Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI. Partnership ensures... ► Artikel lesen | |
| 07.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.04. | RADIOPHARM THERANOSTICS LIMITED: RAD and Siemens Sign Clinical Supply Agreement for RAD101 | - | ASX | ||
| 31.03. | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notice (IT) | 8 | ASX | ||
| 27.03. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.03. | Radiopharm doses first patient in RAD 402 prostate cancer trial | 1 | Investing.com | ||
| 27.03. | Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer | 190 | GlobeNewswire (Europe) | On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinical... ► Artikel lesen |
1 2 3 4 5 Weiter >>
94 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS | 21,530 | +0,21 % | Servier completes the acquisition of Day One Biopharmaceuticals | Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of... ► Artikel lesen | |
| QIAGEN | 32,580 | -4,39 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| EVOTEC | 5,370 | -5,54 % | Shortseller-Positionen aktuell: u.a. Auto1, Carl Zeiss Meditec, Evotec, Kontron, Puma, Renk, Verve, Zalando | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIONTECH | 92,35 | -0,59 % | Jetzt einsteigen? BioNTech-Aktie mit Kaufsignal! | Nach dem Abgang der Gründer zeigen sich die BioNTech-Anteile inzwischen erholt. Am Donnerstag ist es sogar zu einem ersten Kaufsignal gekommen. Jetzt zugreifen? BioNTech wird von der starken Branche... ► Artikel lesen | |
| ARCELLX | 115,04 | +0,04 % | Gilead Sciences, Inc. Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 88,82 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026 | ||
| STRYKER | 284,90 | +1,21 % | Following Stryker Cyberattack, Avatier Launches Identity Challenge Card to Protect Organizations When Standard Security Fails | New Solution Delivers the First Auto-Enrolled, Air-Gapped Multi-Factor Authentication (MFA) That Can Be Deployed Enterprise-Wide in a Single Day: No Devices, Apps, or Network Connectivity RequiredPLEASANTON... ► Artikel lesen | |
| NUVALENT | 107,93 | -0,88 % | Nuvalent präsentiert AACR-Daten vor PDUFA-Entscheid im September | ||
| INHIBRX BIOSCIENCES | 125,01 | +8,62 % | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 339,50 | +0,66 % | Praxis Precision Medicines (PRAX): One of the Best Upside Stocks | ||
| MODERNA | 46,705 | -1,69 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 36,780 | 0,00 % | Rapport Therapeutics reports extended efficacy data for RAP-219 | ||
| CLIMB BIO | 9,330 | 0,00 % | Oppenheimer raises Climb Bio stock price target on clinical data | ||
| ERASCA | 21,670 | +0,14 % | Erasca, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 23,600 | -3,95 % | Stifel reiterates Summit Therapeutics stock rating on trial data |
RADIOPHARM THERANOSTICS LIMITED ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,010 (-0,22 %) liegt der Kurs bei 4,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.